Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02490904 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)

Study acronym: EPURE
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv9
  2. Primary completion date changed from estimate of Jul 2020 to Nov 9, 2021v8 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jul 2030 to Aug 2031
    • Start date: Oct 2016 to Oct 19, 2016
    • Site details revised at 7 of 7 sites
  3. Site details revised at 1 of 7 sitesv7
  4. Re-verified, no change to tracked fieldsv6
  5. Interventions: Eplerenon (Drug), Placebo (Drug) to Eplerenone (Drug), Placebo (Drug)
    • Eligibility criteria revised
    • Secondary endpoints: 14 to 13
    • Study sites revised (7)
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv4 Show 6 more changesShow less
    • Start date: May 2016 to Oct 2016
    • Study sites: 6 to 7
    • Primary completion date: Aug 2020 to Jul 2020
    • Study completion date: May 2030 to Jul 2030
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: 13 to 14
  2. Primary completion date: Aug 2019 to Aug 2020
    • Start date: Nov 2015 to May 2016
    • Study completion date: May 2029 to May 2030
    v3
  3. Secondary endpoints revised (13)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Assess the impact of eplerenone (initiated within 2 hours prior to patient departure to the operating room and administered for 4 days during the post-operative period) on graft function evaluated by the measurement of glomerular filtration rate at 3 months - variable strongly associated with long-term graft survival.
Trial Details
NCT Number NCT02490904
Lead Sponsor Central Hospital, Nancy, France
Conditions
(from sponsor)		 End-stage Renal Disease
Related terms Kidney Failure, Chronic
Enrollment 132 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov